Literature DB >> 27074126

Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants.

Dale L Phelps1, Robert M Ward2, Rick L Williams3, Tracy L Nolen3, Kristi L Watterberg4, William Oh5, Michael Goedecke3, Richard A Ehrenkranz6, Timothy Fennell7, Brenda B Poindexter8, C Michael Cotten9, Mikko Hallman10, Ivan D Frantz11, Roger G Faix2, Kristin M Zaterka-Baxter3, Abhik Das12, M Bethany Ball13, Conra Backstrom Lacy4, Michele C Walsh14, Waldemar A Carlo15, Pablo J Sánchez16, Edward F Bell17, Seetha Shankaran18, David P Carlton19, Patricia R Chess1, Rosemary D Higgins20.   

Abstract

BACKGROUND: Preterm infants with respiratory distress syndrome (RDS) given inositol had reduced bronchopulmonary dysplasia (BPD), death and severe retinopathy of prematurity (ROP). We assessed the safety and pharmacokinetics of daily inositol to select a dose providing serum levels previously associated with benefit, and to learn if accumulation occurred when administered throughout the normal period of retinal vascularization.
METHODS: Infants ≤ 29 wk GA (n = 122, 14 centers) were randomized and treated with placebo or inositol at 10, 40, or 80 mg/kg/d. Intravenous administration converted to enteral when feedings were established, and continued to the first of 10 wk, 34 wk postmenstrual age (PMA) or discharge. Serum collection employed a sparse sampling population pharmacokinetics design. Inositol urine losses and feeding intakes were measured. Safety was prospectively monitored.
RESULTS: At 80 mg/kg/d mean serum levels reached 140 mg/l, similar to Hallman's findings. Levels declined after 2 wk, converging in all groups by 6 wk. Analyses showed a mean volume of distribution 0.657 l/kg, clearance 0.058 l/kg/h, and half-life 7.90 h. Adverse events and comorbidities were fewer in the inositol groups, but not significantly so.
CONCLUSION: Multiple dose inositol at 80 mg/kg/d was not associated with increased adverse events, achieves previously effective serum levels, and is appropriate for investigation in a phase III trial.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27074126      PMCID: PMC5198845          DOI: 10.1038/pr.2016.97

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  24 in total

Review 1.  The International Classification of Retinopathy of Prematurity revisited.

Authors: 
Journal:  Arch Ophthalmol       Date:  2005-07

2.  Screening examination of premature infants for retinopathy of prematurity.

Authors: 
Journal:  Pediatrics       Date:  2006-02       Impact factor: 7.124

3.  Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.

Authors:  Julie Bertrand; Emmanuelle Comets; France Mentre
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

Review 4.  Retinopathy of prematurity.

Authors:  Ann Hellström; Lois E H Smith; Olaf Dammann
Journal:  Lancet       Date:  2013-06-17       Impact factor: 79.321

5.  Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network.

Authors:  Barbara J Stoll; Nellie I Hansen; Edward F Bell; Seetha Shankaran; Abbot R Laptook; Michele C Walsh; Ellen C Hale; Nancy S Newman; Kurt Schibler; Waldemar A Carlo; Kathleen A Kennedy; Brenda B Poindexter; Neil N Finer; Richard A Ehrenkranz; Shahnaz Duara; Pablo J Sánchez; T Michael O'Shea; Ronald N Goldberg; Krisa P Van Meurs; Roger G Faix; Dale L Phelps; Ivan D Frantz; Kristi L Watterberg; Shampa Saha; Abhik Das; Rosemary D Higgins
Journal:  Pediatrics       Date:  2010-08-23       Impact factor: 7.124

6.  Some considerations on the design of population pharmacokinetic studies.

Authors:  Stephen Duffull; Tim Waterhouse; John Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

7.  Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies.

Authors:  James D Reynolds; Velma Dobson; Graham E Quinn; Alistair R Fielder; Earl A Palmer; Richard A Saunders; Robert J Hardy; Dale L Phelps; John D Baker; Michael T Trese; David Schaffer; Betty Tung
Journal:  Arch Ophthalmol       Date:  2002-11

8.  Perinatal development of inositol synthesis and catabolism in rabbit kidney.

Authors:  K Bry; M Hallman
Journal:  Biol Neonate       Date:  1991

9.  Neurodevelopmental outcome of extremely low birth weight infants with Candida infection.

Authors:  Ira Adams-Chapman; Carla M Bann; Abhik Das; Ronald N Goldberg; Barbara J Stoll; Michele C Walsh; Pablo J Sánchez; Rosemary D Higgins; Seetha Shankaran; Kristi L Watterberg; Shahnaz Duara; Nancy A Miller; Roy J Heyne; Myriam Peralta-Carcelen; Ricki F Goldstein; Jean J Steichen; Charles R Bauer; Susan R Hintz; Patricia W Evans; Michael J Acarregui; Gary J Myers; Betty R Vohr; Deanne E Wilson-Costello; Athina Pappas; Yvonne E Vaucher; Richard A Ehrenkranz; Elisabeth C McGowan; Robert G Dillard; Janell Fuller; Daniel K Benjamin
Journal:  J Pediatr       Date:  2013-05-30       Impact factor: 4.406

Review 10.  Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010.

Authors:  Hannah Blencowe; Joy E Lawn; Thomas Vazquez; Alistair Fielder; Clare Gilbert
Journal:  Pediatr Res       Date:  2013-12       Impact factor: 3.756

View more
  12 in total

1.  An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.

Authors:  Clément Larrue; Nastassja K Scheidegger; Shan Lin; Bo Kyung A Seong; Neekesh V Dharia; Miljan Kuljanin; Caroline S Wechsler; Guillaume Kugener; Amanda L Robichaud; Amy Saur Conway; Thelma Mashaka; Sarah Mouche; Biniam Adane; Jeremy A Ryan; Joseph D Mancias; Scott T Younger; Federica Piccioni; Lynn H Lee; Mark Wunderlich; Anthony Letai; Jérôme Tamburini; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2021-09-16       Impact factor: 38.272

2.  Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial.

Authors:  Dale L Phelps; Kristi L Watterberg; Tracy L Nolen; Carol A Cole; C Michael Cotten; William Oh; Brenda B Poindexter; Kristin M Zaterka-Baxter; Abhik Das; Conra Backstrom Lacy; Ann Marie Scorsone; Michele C Walsh; Edward F Bell; Kathleen A Kennedy; Kurt Schibler; Gregory M Sokol; Matthew M Laughon; Satyanarayana Lakshminrusimha; William E Truog; Meena Garg; Waldemar A Carlo; Abbot R Laptook; Krisa P Van Meurs; David P Carlton; Amanda Graf; Sara B DeMauro; Luc P Brion; Seetha Shankaran; Faruk H Orge; Richard J Olson; Helen Mintz-Hittner; Michael B Yang; Kathryn M Haider; David K Wallace; Mina Chung; Denise Hug; Irena Tsui; Martin S Cogen; John P Donahue; Michael Gaynon; Amy K Hutchinson; Don L Bremer; Graham Quinn; Yu-Guang He; William R Lucas; Timothy W Winter; Stephen D Kicklighter; Kartik Kumar; Patricia R Chess; Tarah T Colaizy; Anna Marie Hibbs; Namasivayam Ambalavanan; Heidi M Harmon; Elisabeth C McGowan; Rosemary D Higgins
Journal:  JAMA       Date:  2018-10-23       Impact factor: 56.272

3.  Eligibility Criteria and Representativeness of Randomized Clinical Trials That Include Infants Born Extremely Premature: A Systematic Review.

Authors:  Leeann R Pavlek; Brian K Rivera; Charles V Smith; Joanie Randle; Cory Hanlon; Kristi Small; Edward F Bell; Matthew A Rysavy; Sara Conroy; Carl H Backes
Journal:  J Pediatr       Date:  2021-04-21       Impact factor: 6.314

4.  Inositol in preterm infants at risk for or having respiratory distress syndrome.

Authors:  Alexandra Howlett; Arne Ohlsson; Nishad Plakkal
Journal:  Cochrane Database Syst Rev       Date:  2019-07-08

5.  Respiratory metabolites in bronchoalveolar lavage fluid (BALF) and exhaled breath condensate (EBC) can differentiate horses affected by severe equine asthma from healthy horses.

Authors:  Marilena Bazzano; Luca Laghi; Chenglin Zhu; Gian Enrico Magi; Beniamino Tesei; Fulvio Laus
Journal:  BMC Vet Res       Date:  2020-07-08       Impact factor: 2.741

6.  Role of inositol to improve surfactant functions and reduce IL-6 levels: A potential adjuvant strategy for SARS-CoV-2 pneumonia?

Authors:  Antonio Simone Laganà; Vittorio Unfer; Simone Garzon; Mariano Bizzarri
Journal:  Med Hypotheses       Date:  2020-09-09       Impact factor: 1.538

Review 7.  Role of cytokines and treatment algorithms in retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Curr Opin Ophthalmol       Date:  2017-05       Impact factor: 3.761

8.  Blood myo-inositol concentrations in preterm and term infants.

Authors:  Luc P Brion; Dale L Phelps; Robert M Ward; Tracy L Nolen; N Mikko K Hallman; Abhik Das; Daniel J Zaccaro; M Bethany Ball; Kristi L Watterberg; Ivan D Frantz; C Michael Cotten; Brenda B Poindexter; William Oh; Ralph A Lugo; Krisa P Van Meurs; T Michael O'Shea; Kristin M Zaterka-Baxter; Rosemary D Higgins
Journal:  J Perinatol       Date:  2020-09-15       Impact factor: 2.521

9.  A clinical study on plasma biomarkers for deciding the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia of premature infants.

Authors:  Haiyan Zhu; Yian Tian; Huaiping Cheng; Yafei Zheng; Wei Wang; Tianping Bao; Rong Wu; Zhaofang Tian
Journal:  Int J Med Sci       Date:  2021-04-29       Impact factor: 3.738

Review 10.  Opportunities in posthemorrhagic hydrocephalus research: outcomes of the Hydrocephalus Association Posthemorrhagic Hydrocephalus Workshop.

Authors:  Jenna E Koschnitzky; Richard F Keep; David D Limbrick; James P McAllister; Jill A Morris; Jennifer Strahle; Yun C Yung
Journal:  Fluids Barriers CNS       Date:  2018-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.